Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, Duffin KL, Robins DA, Haupt A. Hartman ML, et al. Among authors: karanikas ca. Diabetes Care. 2020 Jun;43(6):1352-1355. doi: 10.2337/dc19-1892. Epub 2020 Apr 14. Diabetes Care. 2020. PMID: 32291277 Free PMC article. Clinical Trial.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Boye KS, Riddle MC, Gerstein HC, Mody R, Garcia-Perez LE, Karanikas CA, Lage MJ, Riesmeyer JS, Lakshmanan MC. Boye KS, et al. Among authors: karanikas ca. Diabetes Obes Metab. 2019 Jun;21(6):1299-1304. doi: 10.1111/dom.13649. Epub 2019 Mar 12. Diabetes Obes Metab. 2019. PMID: 30714309 Free PMC article.
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Mari A, Del Prato S, Ludvik B, Milicevic Z, de la Peña A, Shurzinske L, Karanikas CA, Pechtner V. Mari A, et al. Among authors: karanikas ca. Diabetes Obes Metab. 2016 Aug;18(8):834-9. doi: 10.1111/dom.12671. Epub 2016 May 16. Diabetes Obes Metab. 2016. PMID: 27059816